AiCoin｜6.29 Snapshot: Strategic Reserve Plan, US-Iran Negotiations Suspended, Grayscale Sells BTC

Getlink disclosed 550,000,000 ordinary shares outstanding as of Sept. 30, 2026. Theoretical voting rights totaled 642,851,718. Exercisable voting rights stood at 635,332,063. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Getlink SE published the original content used to generate this news brief via Business Wire (Ref. ID: 202610051200BIZWIRE_USPR_____20261005_BW048564) on October 05, 2026, and is solely responsible for the information contained therein.

11:12 AM EDT, 10/05/2026 (MT Newswires) -- European equities traded in the US as American depositary receipts opened the week lower late Monday morning, declining 0.14% to 1,883.96 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by lender Banco Santander (SAN) and brewing company Anheuser-Busch InBev (BUD), which advanced 3.2% and 0.8% respectively. They were followed by 3D printer company Materialise (MTLS) and internet browser company Opera (OPRA), which were up 0.6% and 0.3% respectively. The decliners from continental Europe were led by biopharmaceutical company Nokia (NOK) and biopharmaceutical company Cellectis (CLLS), which lost 3.2% each. They were followed by biopharmaceutical company DBV Technologies (DBVT) and petroleum refiner Equinor (EQNR), which decreased 0.9% and 0.4%, respectively. The gainers from the UK were led by biopharmaceutical company Bicycle Therapeutics (BCYC) and software firm Endava plc (DAVA), which climbed 17% and 1.6% respectively. They were followed by medical device maker Smith & Nephew (SNN) and biotech firm Trinity Biotech (TRIB), which increased 1.2% and 1.4% respectively. The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which dropped 3.9% and 1.4% respectively. They were followed by hospitality company InterContinental Hotels Group (IHG) and pharmaceutical company GSK (GSK), which fell 1.1% and 1% respectively.

Latest updates as of October 5: - Pharmaceutical company Insmed (INSM.O) shares fell by 8.4%, closing at $101.93. - Sara Bonstein will step down as Chief Financial Officer, effective October 30. - Insmed was mentioned in analyst reports as a potential acquisition target (link). - “One possible reason for today's decline in share price is that the CFO's departure may lead investors to believe an acquisition is less likely in the short term—we note that recent discussions among investors about this possibility have increased,” RBC Capital Markets added. - The company reaffirmed its fiscal 2026 performance guidance and stated it has begun the search for the next CFO. - RBC described the transition as “overall positive,” and noted that since the CFO change will occur after Insmed releases its Q3 results on October 29, the timing should help ensure a smooth transition. - Including intraday fluctuations, the stock has dropped 41.3% year-to-date. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may be inaccurate or may not include all desired context, Reuters does not guarantee the accuracy of the translated texts, which are provided solely for reader convenience. Reuters is not liable for any damages or losses resulting from the use of this automated translation.)